Trial Profile
A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Atezolizumab (MPDL3280A) Administered Intravenously as a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Advanced breast cancer; Bladder cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Glioblastoma; Haematological malignancies; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer; Uveal melanoma
- Focus Adverse reactions; First in man
- Sponsors Genentech; Roche
- 10 Feb 2021 Results (n=35) from mCRPC cohort published in the Clinical Cancer Research
- 18 Jun 2020 Results to identify and validate a prognostic model for survival consisting of some the aforementioned routinely measured and available standardized clinical and analytically validated laboratory factors in the setting of PD-1/PD-L1 inhibitors administered for progressive mUC following platinum-based chemotherapy published in the Journal of Urology
- 29 Jul 2019 Results (n=45) assessing tolerability of atezolizumab in metastatic melanoma patients, published in the Clinical Cancer Research.